Slide 1: Q2 2025 Earnings Presentation
BRUKER CORPORATION (NASDAQ: BRKR) Q2 2025 Earnings Presentation August 4, 2025 Frank H. Laukien, President & Chief Executive Officer Gerald Herman, Executive Vice President & Chief Financial Officer Joe Kostka, Director, Investor Relations
Slide 2: Safe Harbor Statement
BRUKER CORP ORATI ON Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 193
Slide 3: Business Update
Q2 2025 Business Update 3
Slide 4: Q2 2025: Organic revenue, non-GAAP operating margin and EPS decline
Q2 2025: Organic revenue, non-GAAP operating margin and EPS decline on research instruments, tariff, and FX headwinds Q2 2025 Performance; Year-over-Year Changes Q2 Financials Revenues [$M] ❖ Revenue decrease of -$3.3M, or -0.4% ▪ Constant-exchange rate (CER) decline of -3.3% 797.4 800.7 -0.4% ▪ Org
Slide 5: H1 2025: Revenue growth driven by acquisitions; margin and EPS down
H1 2025: Revenue growth driven by acquisitions; non-GAAP operating margin and EPS down on research instruments, tariff, and FX headwinds H1 2025 Performance; Year-over-Year Changes H1 Financials Revenues [$M] ❖ Revenue increase of $76.4M, or 5.0% ▪ Constant-exchange rate (CER) growth of 4.2% 1598.8
Slide 6: Group CER H1 2025 Revenue Performance YoY
GROUP OVERVIEW Group CER H1 2025 Revenue Performance YoY Bruker BIOSPIN Group ▪ BIOSPIN CER revenue roughly flat ▪ Growth contributions from NMR, lab automation, and preclinical imaging ▪ Uncertainty in US, Europe led to weakness in biopharma ▪ Macro uncertainty impacted scientific software demand b
Slide 7: Group CER H1 2025 Revenue Performance YoY
GROUP OVERVIEW Group CER H1 2025 Revenue Performance YoY Bruker NANO Group ▪ NANO CER revenue up low single digits% ▪ Growth driven by Spatial Biology, driven by Nanostring ▪ Softness in X-Ray and NanoAnalysis tools ▪ Strong growth in Japan and North America, softness in China Bruker Energy & Superc
Slide 8: Recent Innovations at ASMS: Advancing Proteomics and Multiomics
IN N OVATION EN G IN E Recent Innovations at ASMS: Advancing Proteomics and Multiomics with Pioneering, Best-in-Class Platforms in Mass Spectrometry timsOmni timsMetabo Ushers in an era of functional proteomics Benchtop 4D-Metabolomics for and proteoform analysis – at depth unprecedented annotation
Slide 9: Mitigation Actions
COST SAVINGS IN ITIATIVES Navigating through Macro & Research Instruments Weakness Macro & Market Challenges US Academic China Stimulus Drug Discovery & Tariff Uncertainties; Funding Disruption Delays Industrial Research Tariff and FX Capex Delays Cost Headwinds Mitigation Actions 1 Industry-Leading
Slide 10: Financial Update
Q2 2025 Financial Update 10
Slide 11: Q2 2025 Selected Non-GAAP Financial Measures
Q2 2025 YEAR-OVER-YEAR COMPARISON Q2 2025 Selected Non-GAAP Financial Measures1 [$ m, except EPS] Q2 2025 Q2 2024 Δ Comments (year-over-year) Total Revenues 797.4 800.7 (0.4%) ▪ Revenue decline of -0.4% Gross Profit 387.2 411.1 (5.8%) Margin (% of revenues) 48.6% 51.3% -270 bps ▪ BSI organic revenue
Slide 12: H1 2025 Selected Non-GAAP Financial Measures
H1 2025 YEAR-OVER-YEAR COMPARISON H1 2025 Selected Non-GAAP Financial Measures1 [$ m, except EPS] H1 2025 H1 2024 Δ Comments (year-over-year) Total Revenues 1,598.8 1,522.4 5.0% ▪ Revenue growth of 5.0% Gross Profit 798.1 780.5 2.3% Margin (% of revenues) 49.9% 51.3% -140 bps ▪ BSI organic revenue d
Slide 13: H1 Selected Cash Flow And Balance Sheet Financial Measures
H1 2025 YEAR-OVER-YEAR COMPARISON H1 Selected Cash Flow And Balance Sheet Financial Measures [$M] H1 2025 H1 2024 Δ Comments (year-over-year) GAAP Net Income 21.0 59.6 (38.6) Depreciation & amortization 106.5 79.9 26.6 ▪ Free cash flow down -$86.7M, impacted Changes in working capital 12.5 (61.1) 73
Slide 14: Updated FY 2025 Outlook
CEQ) So ad - Updated FY 2025 Outlook
Slide 15: Updated FY 2025 Financial Outlook (as of August 4, 2025)
Updated FY 2025 Financial Outlook (as of August 4 , 2025) th Non-GAAP Assumptions & YoY Estimates FY 2025 Guidance (year-over-year %s) ▪ FY25 operating margin down ~210 bps yoy Revenue $3.43B to $3.50B ▪ Organic -20bps; M&A -40bps; Tariffs -60bps; FX -90bps Reported Revenue Growth +2% to +4% ▪ FX im
Slide 16: Supplementary Financial Information
Supplementary Financial Information* * - For preliminary financial statements, GAAP to Non-GAAP reconciliations, and other supplementary financial information, please refer to our Q2 2025 Earnings Press Release issued August 4th, 2025. 16
Slide 17: ;
;